A Phase 3 interventional study of Trazodone and Sentra PM in Sleep Disorder, sponsored by Targeted Medical Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-11-09.
Sponsored by Targeted Medical Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Sleep Wake Disorders with a site in United States — 34 open to participants now, 40 under way, 8 of them phase 3. Sleep Wake Disorders · United States.
Among the 248 studies in Sleep Wake Disorders with a site in United States, this one is the 79th largest by enrollment of the 203 interventional ones that give a count, is one of 9 that started in 2008, is one of 26 in phase 3, and was the 101st registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.
Browse Sleep Wake Disorders studies →34 of the 248 studies in Sleep Wake Disorders with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Alkermes, Inc. · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–70
Centessa Pharmaceuticals (UK) Limited · Sites in United States
Ages 18–70
VA Office of Research and Development · Sites in United States
Ages 60+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 110 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 54 (49%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 30 · Phase 4 19
First in 1996; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 70 across the 203 interventional studies, 110 across the 44 observational. Of the 189 that completed or were terminated, 67 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 248 have an industry lead sponsor. The 10 most frequent:
Targeted Medical Pharma is the lead sponsor of 7 studies on the registry; none are open to participants now.
Targeted Medical Pharma has 1 study filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Sleep Wake Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07540897Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | 2027-06 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 248 studies in Sleep Wake Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double blind placebo controlled study of one hundred and four subjects which will be randomized for treatment with Sentra PM alone, Sentra PM with trazadone, trazadone alone and placebo alone. Twenty -six subjects will be randomly placed in one of the four groups. Each of the one hundred and four subjects will undergo baseline examination to include a sleep study questionnaires and 24- hour electrocardiographic recording. The one hundred and four subjects will then be randomly placed in one of the four groups.
Sentra PM can induce restorative sleep compared to placebo, and as good as a sleep drug (trazadone) in subjects experiencing non-restorative sleep. Sentra PM taken with trazadone works better than either product alone. Twenty-six subjects will be randomized to a two week ingestion of Sentra PM at bedtime, twenty-six subjects will be randomized to a two week ingestion of trazadone at bedtime, twenty-six subjects will be randomized to a two week ingestion of Sentra PM with trazadone at bedtime and twenty -six subjects will be randomized to a two week ingestion of placebo at bedtime. Each morning after ingestion of either active product or placebo, the subject will fill out sleep questionnaires. On the fourteenth day of ingestion, a repeat 24-Hour ECG examination will be performed on all one hundred and four subjects and each subject will give a second blood sample for analysis. On the morning of the 14th day of ingestion the final sleep questionnaires will be completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
trazodone 50mg with Sentra PM-like placebo
Drug: Trazodone
Trazodone-like placebo and Sentra PM
Other: Sentra PM
Active Sentra PM and active trazodone
Drug: Sentra PM and Trazodone (CoPack Kit Trazamine)
trazadone-like placebo and Sentra PM-like placebo
Drug: Placebo trazodone and placebo Sentra PM
active trazodone and sentra pm-like placebo
Active Sentra PM and trazodone-like placebo
A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
Time to fall asleep
Subjects time to fall asleep will be measure by patient response to questionnaires to determine if time improved, stayed the same or worsen.
Time frame: 14 days
Quality of Sleep
Time frame: 14 days
Morning grogginess
Time frame: 14 days
Feelings of depression
Time frame: 14 days
Feelings of anxiety
Time frame: 14 days
Improvement in parasympathetic activity
Improved parasympathetic activity measured by 24 hour ECG holter moniter.
Time frame: 14 days
The record gives a start of Apr 2008, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Targeted Medical Pharma